Xiamen Innovax Biotech
From Wikipedia the free encyclopedia
 | This article reads like a press release or a news article and may be largely based on routine coverage. (July 2021) |
Xiamen Innovax Biotech CO., LTD. (Innovax) is a Chinese company that manufactures, markets, and develops vaccines. It is headquartered in Xiamen, Fujian, China.[1][2]
Hepatitis E Vaccine (HEV 239)[edit]
In October 2012, Xiamen created the HEV 239 vaccine to treat Hepatitis E. The vaccine was approved by the Chinese Ministry of Science and Technology after it was tested during a controlled trial of 100,000+ people from the Jiangsu Province over a 12-month period. Of the 100,000 people treated, none were infected as compared to 15 that were infected from the controlled placebo group.[3][4][5]
Other vaccines[edit]
The firm also has created a cervical cancer vaccine that is currently under a phase III clinical trial,[6] a genital warts vaccine that is under a phase II clinical trial,[7] and a 9-valent HPV vaccine currently in the process of receiving clinical approval.[8]
WHO position on HEV 239[edit]
The World Health Organization (WHO) stated that the Phase I, II, and III clinical trials were effective and safe in healthy subjects, however the WHO has not made a recommendation regarding the HEV 239 Vaccine because of a lack of evidence in people 16 years of age or younger, and 65 years of age and older. China is currently the only country to approve the vaccine since Hepatitis E is rare in developed countries. There are further clinical trials planned before making the drug more generally available. to susceptible populations.[9] The position of the WHO is that, however, national authorities may decide to use the vaccine based on the local epidemiology.[9]
References[edit]
- ^ "First hepatitis E vaccine hits market in China". China Daily. Retrieved August 8, 2017.
- ^ "China Approves World's First Hepatitis E Vaccine". Asian Scientist. 23 January 2012. Retrieved August 8, 2017.
- ^ Labrique, Alain B.; Sikder, Shegufta S.; Krain, Lisa J.; West, Keith P.; Christian, Parul; Rashid, Mahbubur; Nelson, Kenrad E. (2012-09-01). "Hepatitis E, a Vaccine-Preventable Cause of Maternal Deaths". Emerging Infectious Diseases. 18 (9): 1401–1404. doi:10.3201/eid1809.120241. ISSN 1080-6040. PMC 3437697. PMID 22931753.
- ^ "Health in the Future: Hepatitis E to Z". Independent UK. 18 September 2011. Retrieved August 8, 2017.
- ^ Park, S. B. (November 2012). "Hepatitis E vaccine debuts". Nature. 491 (7422): 21–22. Bibcode:2012Natur.491...21P. doi:10.1038/491021a. PMID 23128204.
- ^ Hu, Yuemei (October 2013). "Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine". Human Vaccines & Immunotherapeutics. 52 (3): 218–23. doi:10.4161/hv.26846. PMC 4185883. PMID 24161937.
- ^ "Human papillomavirus 6/11 vaccine recombinant bivalent". Adis Insight.
- ^ "Meeting on Appropriate Clinical Endpoints for Second Generation HPV Vaccine Trials" (PDF). WHO Immunization Research: 1–2. 19 November 2013.
- ^ a b "Hepatitis E vaccine: WHO position paper, May 2015" (PDF). Relevé Épidémiologique Hebdomadaire. 90 (18): 185–200. 1 May 2015. PMID 25935931.